Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, comments on the results of an analysis comparing patient-reported outcomes in patients with relapsed/refractory (R/R) multiple myeloma from the CARTITUDE-1 (NCT03548207) and LocoMMotion (NCT04035226) studies. The study reported an initial decrease in quality of life (QoL) in patients treated with ciltacabtagene autoleucel (cilta-cel) seven days after CAR-T infusion, which was likely due to therapy-related adverse events. However, several months after treatment, patients treated with cilta-cel had improved patient-reported outcomes (PROs) in comparison to patients treated with other regimens. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.